CD8A and neoplasm: Peritumoral administration of HP-NAP resulted in a reduction of tumorigenesis, promotion of tumor necrosis, and augmentation of CD4 + and CD8 + cell populations secreting IFN-γ within both tumor sites and associated lymph nodes [219].